NCT04162210 · OUTCOME

Overall Survival (OS)

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) · Source last updated 2026-07-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: Months
Interval / dispersion: 95% Confidence Interval
Time frame: Up to approximately 263 weeks

What was measured

OS is defined as the time from randomization until death due to any cause.

Analysis population: ITT Population

Groups in this outcome

Belantamab Mafodotin

Participants with relapsed/refractory multiple myeloma (RRMM) received 30 minutes intravenous infusion of 2.5 milligram/kilogram (mg/kg) belantamab mafodotin on day 1 of each 21-day cycle

Pomalidomide Plus Dexamethasone

Participants with RRMM received 4 mg pomalidomide capsule daily on Days 1 to 21 of each 28-day cycle, along with 40 mg or at lower 20 mg (for participants \>75 years of age) dose of dexamethasone tablet once weekly (Days 1, 8, 15 and 22)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Belantamab Mafodotin	218
Pomalidomide Plus Dexamethasone	107

Reported measurements

Source class 1

Values in Months · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Belantamab Mafodotin	24.0	Not reported	19.4	33.2	Not reported
Pomalidomide Plus Dexamethasone	22.9	Not reported	16.0	29.3	Not reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

ci Lower Limit
0.73
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
1.30
group Ids
OG000
OG001
non Inferiority Type
OTHER
p Value
0.440
param Type
Hazard Ratio (HR)
param Value
0.98
statistical Comment
One-sided p-value from stratified log-rank test were adjusted for previous treatment with anti-CD38, ISS staging and number of prior lines of therapy.
statistical Method
Log Rank

Complete source fields

analyses

ci Lower Limit
0.73
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
1.30
group Ids
OG000
OG001
non Inferiority Type
OTHER
p Value
0.440
param Type
Hazard Ratio (HR)
param Value
0.98
statistical Comment
One-sided p-value from stratified log-rank test were adjusted for previous treatment with anti-CD38, ISS staging and number of prior lines of therapy.
statistical Method
Log Rank

classes

categories
measurements
group Id
OG000
lower Limit
19.4
upper Limit
33.2
value
24.0
group Id
OG001
lower Limit
16.0
upper Limit
29.3
value
22.9

denoms

counts
group Id
OG000
value
218
group Id
OG001
value
107
units
Participants

description

OS is defined as the time from randomization until death due to any cause.

dispersion Type

95% Confidence Interval

groups

description
Participants with relapsed/refractory multiple myeloma (RRMM) received 30 minutes intravenous infusion of 2.5 milligram/kilogram (mg/kg) belantamab mafodotin on day 1 of each 21-day cycle
id
OG000
title
Belantamab Mafodotin
description
Participants with RRMM received 4 mg pomalidomide capsule daily on Days 1 to 21 of each 28-day cycle, along with 40 mg or at lower 20 mg (for participants \>75 years of age) dose of dexamethasone tablet once weekly (Days 1, 8, 15 and 22)
id
OG001
title
Pomalidomide Plus Dexamethasone

param Type

MEDIAN

population Description

ITT Population

reporting Status

POSTED

time Frame

Up to approximately 263 weeks

title

Overall Survival (OS)

type

SECONDARY

unit Of Measure

Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice